Translational Development Acquisition Corp.

Translational Development Acquisition Corp., trading under the warrant ticker TDACW, is a blank-check company focused on the life sciences and healthcare sector. The vehicle filed a Form 10-Q with the Securities and Exchange Commission on November 14, 2025, under accession number 0001104659-25-112494, confirming it remains an active reporting entity in its post-IPO phase. The company name references translational medicine, signaling a mandate oriented toward biotechnology, pharmaceutical development, or adjacent healthcare verticals. The warrant listing indicates no de-SPAC transaction has yet closed. For the full sponsor profile, IPO details, filing history, and deal intelligence on TDACW, sign up for a free account at SpacDesk.